NASDAQ
|
Healthcare
|
Drug Manufacturers—Specialty & Generic
Q123reported Nov 7, 2022 Reporting Period
$269.66M4.6%
vs. Q122
Revenues Q123
66.6%0.4%
vs. Q122
Gross Profit Margin
33.21%
22.9%
vs. Q122 Net Profit Margin
46.53M -3.9%
vs. Q122
Free Cash Flow Q123
$0.55 30.6%
vs. Q122
EPS Q123
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q123
0.11%
Q322
1.41%
Q322reported Nov 7, 2022 Reporting Period
$4.08B
-10.1%
vs. Q321
Revenues Q322
42.87%23.6%
vs. Q321 Gross Profit Margin
8.69%
26.5%
vs. Q321 Net Profit Margin
753.3M
-30.6% vs. Q321 Free Cash Flow Q322
$0.29
11.5% vs. Q321 EPS Q322
-
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q123
0.11%
Q322
1.41%
Loading...
Loading...
Loading...
Loading...
Ratios
As of
Sep 30, 2022
Sep 30, 2022
Quick Ratio
2.74
0.66
Current Ratio
4.01
1.61
Cash Ratio
1.2
0.1
Price to Book
6.36
0.54
Price to Sales
41.32
2.53
Price to Earnings
31.1
7.29
Feedback
Disclaimer
The content of this website is for informational purposes only, you should not construe any such information or other material as legal, tax, investment,
financial, or other advice. Nothing contained on this website constitutes professional and/or financial advice, nor does any information on the website constitute a comprehensive or complete statement of the matters discussed or the law relating thereto.
In order to make the best financial decision that suits your own needs, you must conduct your own research and seek the advice of a licensed financial advisor if necessary.
Data
The financial data on StocksFin comes directly from SEC.gov.
We use a third party service (financialmodelingprep) to crawl, reprocess and organize such data in a readable manner. If you encounter any inacurracy in the data, please let us know.
We use Google Analytics to track users sessions on this website. You can block such tracking by using a GA opt-out add-on.
